Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,137.90
(
1.05%
)
US TECH 100
26,218.00
(
1.73%
)
Dow Jones
49,490.03
(
0.09%
)
Brent Oil
98.27
(
1.60%
)
Bitcoin
78,036.03
(
-0.26%
)
News Focus
News Focus
Post# of 257438
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

biomaven0

Send PM Follow Ignore
Followers 82
Posts 4778
Boards Moderated 0
Alias Born 02/27/2007

biomaven0

Re: DewDiligence post# 127359

Monday, 09/26/2011 2:12:21 PM

Monday, September 26, 2011 2:12:21 PM

Post# of 257438

NVS expects Gleevec generics to launch in the US market when the 5521184 composition-of-matter patent expires in Jul 2015.



I assume they are just being conservative in their forecasting here? Novartis do have the listed formulation patents going through 2019 - Sun will either have to show non-infringement, overturn them, or settle.

Peter
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today